Mckinley Capital Management LLC Abb Vie Inc. Transaction History

Mckinley Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$144.61 - $166.54 $52,638 - $60,620	-364 Reduced 2.44%	14,579 $2.32 Million
Q4 2022 Jan 18, 2023	SELL	$138.31 - $165.87 $17,012 - $20,402	-123 Reduced 0.82%	14,943 $0
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $604,347 - $693,146	4,503 Added 42.63%	15,066 $2.02 Million
Q2 2022 Aug 05, 2022	BUY	$137.62 - $174.96 $1.45 Million - $1.85 Million	10,563 New	10,563 $1.62 Million
Q3 2018 Nov 08, 2018	SELL	$88.91 - $98.84 $22.3 Million - $24.8 Million	-251,038 Closed	0 $0
Q2 2018 Jul 13, 2018	SELL	$89.78 - $106.23 $5.53 Million - $6.54 Million	-61,581 Reduced 19.7%	251,038 $23.3 Million
Q1 2018 May 04, 2018	SELL	$92.01 - $123.21 $1.94 Million - $2.59 Million	-21,038 Reduced 6.31%	312,619 $29.6 Million
Q4 2017 Feb 08, 2018	BUY	$89.56 - $98.21 $8.51 Million - $9.33 Million	94,985 Added 39.8%	333,657 $32.3 Million
Q3 2017 Nov 13, 2017	BUY	$69.85 - $89.22 $12.5 Million - $16 Million	179,405 Added 302.71%	238,672 $21.2 Million
Q2 2017 Aug 14, 2017	BUY	N/A	59,267	59,267 $4.3 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Mckinley Capital Management LLC , based on Form 13F filings with the SEC.

Stay updated on Mckinley Capital Management LLC with notifications on news.